Home/Filings/4/0001493152-20-019013
4//SEC Filing

Dickason David 4

Accession 0001493152-20-019013

CIK 0000849636other

Filed

Oct 5, 8:00 PM ET

Accepted

Oct 6, 3:20 PM ET

Size

5.5 KB

Accession

0001493152-20-019013

Insider Transaction Report

Form 4
Period: 2020-09-30
Dickason David
SVP of Pre-Clinical Prod. Dev.
Transactions
  • Award

    Common Stock Options (to purchase shares of Common Stock)

    2020-09-30+2,000,0002,000,000 total
    Exercise: $0.01Exp: 2025-09-30Common Stock (2,000,000 underlying)
Footnotes (1)
  • [F1]These Common Stock Options vest in four equal installments: 25 percent on December 31, 2020, 25 percent on March 31, 2021, 25 percent on June 30, 2021, and 25 percent on September 30, 2021.

Documents

1 file

Issuer

RespireRx Pharmaceuticals Inc.

CIK 0000849636

Entity typeother

Related Parties

1
  • filerCIK 0001827349

Filing Metadata

Form type
4
Filed
Oct 5, 8:00 PM ET
Accepted
Oct 6, 3:20 PM ET
Size
5.5 KB